HER2-Positive Metastatic Breast Cancer (mBC)
HER2 amplification drives aggressive breast tumors, but HER2-targeted therapies have transformed survival. Care now involves sequencing monoclonal antibodies, antibody-drug conjugates (ADCs), TKIs, endocrine therapy for HR-positive disease, and CNS-directed approaches.
Diagnosis & Staging
- Confirm HER2 status (IHC 3+, FISH ratio ≥2)
- Evaluate hormone receptor (ER/PR) expression
- Imaging (CT, bone scan/PET) for staging
- Baseline echocardiogram/MUGA to monitor LVEF during HER2 therapy
- Biopsy of metastatic site when feasible (rule out HER2-low or triple-negative conversion)
First-Line Therapy
- Pertuzumab + trastuzumab + taxane (CLEOPATRA regimen) + maintenance HP
- For HR+/HER2+ disease, endocrine therapy may be added after induction
- Monitor cardiac function every 3–4 months
Second-Line
- Trastuzumab deruxtecan (T-DXd) if no contraindication; high response rates including brain metastases
- T-DM1 as alternative if T-DXd not tolerated/available
Later-Line Options
- Tucatinib + trastuzumab + capecitabine (HER2CLIMB) – strong CNS activity
- Other TKIs: neratinib, lapatinib (often with capecitabine)
- Margetuximab for heavily pretreated patients
- Clinical trials (bispecific antibodies, CAR-T, HER2 vaccines)
CNS Disease Management
- SRS or whole-brain radiation depending on lesion number/size
- HER2 agents with CNS penetration (tucatinib, T-DXd) extend systemic control
- Intrathecal trastuzumab for leptomeningeal disease (investigational)
Supportive & Survivorship Care
- Manage neuropathy, cytopenias, diarrhea, nausea
- Monitor LVEF; pause HER2 therapy for drop >10% or <50%
- Fertility/contraception counseling; pregnancy contraindicated during HER2 therapy
- Psychosocial support, palliative care integration early
- Monitor bone health, manage pain, treat thromboembolism risk
Living with HER2+ mBC
- Track treatment cycles, imaging, cardiac tests, side effects, CNS symptoms, HRQoL, and mental health
- Nutrition, exercise, and integrative therapies can ease fatigue
- Maintain open communication with employer/family; plan for caregiving needs
Research & Future Directions
HER2-low targeting, bispecific antibodies (zanidatamab), ADC combinations, and HER2 CAR-T cells promise deeper, durable control.
Experimental & Emerging Treatments
- Bispecific Antibodies & ADC Combos: Zanidatamab + chemotherapy, T-DXd + CDK4/6 inhibitors.
- HER2 CAR-T & TIL Therapy: Early-phase trials exploring cellular immunotherapy.
- HER2 Vaccines: Aim to sustain immune surveillance post-therapy.
- AI-Based Cardiotoxicity Monitoring: Wearables + biomarkers to personalize HER2 therapy breaks.
Track HER2+ mBC with Diagnoza.care
Sequence Therapies with Clarity – Log regimens, cycle dates, labs, scans, LVEF, symptoms, supportive meds, CNS status, and clinical trial options; capture side effects; and let the AI companion remind you of imaging, cardiology checks, and patient-reported outcome surveys.
Medical Disclaimer: Informational only. Follow your oncologist’s plan for systemic therapy sequencing, cardiac monitoring, CNS management, and clinical trial enrollment.
Sources: NCCN Breast Cancer Guidelines, ASCO, ESMO